Equity Overview
Price & Market Data
Price: $1.06
Daily Change: -$0.12 / 11.32%
Daily Range: $1.04 - $1.19
Market Cap: $3,449,688
Daily Volume: 66,891
Performance Metrics
1 Week: 2.91%
1 Month: -48.04%
3 Months: -49.76%
6 Months: -67.98%
1 Year: -92.87%
YTD: -41.11%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.